Early Evidence of Safety, Clinical Benefit, and Pharmacokinetics of Roflumilast Cream 0.3% Once Daily for Treatment of Mild or Moderate Plaque Psoriasis in Children Aged 2–11 Years

Documenti analoghi

• Long‐Term Safety and Efficacy of Once‐Daily and Proactive Twice‐Weekly Roflumilast Cream 0.05% for Mild‐to‐Moderate Atopic Dermatitis in Children Aged 2–5 Years From a 52‐Week, Phase 3 Trial ( INTEGUMENT ‐ OLE )
  di: Lawrence F. Eichenfield, et al.
  Pubblicazione: (2026)
• Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Secukinumab: Dose Exploration in Pediatric Patients with Plaque Psoriasis
  di: Liu Zhiwei, et al.
  Pubblicazione: (2025)
• Clinical Efficacy and Safety of Topical Roflumilast in Psoriasis: An Updated Systematic Review and Meta‐Analysis of Randomized Controlled Trials
  di: Aimal A. Khattak, et al.
  Pubblicazione: (2025)
• A Case of Palmoplantar Psoriasis Successfully Treated With Tapinarof Cream
  di: Ayako Hiraishi, et al.
  Pubblicazione: (2025)
• Economics and the University Library
  di: Burnett, David
  Pubblicazione: (1970)